What can be expected as the Zika outbreak progresses? Which areas are going to be the most affected? This Visiongain report discusses the future direction of the Zika virus outbreak and the implications of its spread. It also discussed the infectious disease diagnostics market and the global human vaccines market, both of which are forecast to 2026. The pipeline for Zika virus diagnostics and vaccines is explored.
Our 78-page report provides 28 tables, charts, and graphs. Understand the virus and the future of the current outbreak. Our new study lets you assess the impact the virus might have on a number of regions, and the complications that have so far been associated with it.
Forecasts from 2016-2026 and other analyses show you commercial prospects This report provides forecasts for both the infectious disease diagnostics market and the human vaccines market to 2026, and discussed the possible future contributors to these markets in relation to the Zika virus. Discover the symptoms, transmission, history and economic and social impacts of this virus.
See revenue forecasts for the associated markets How will associated markets perform to 2026? Our study forecasts revenues in the following related markets: • Infectious Disease Diagnostics Market • Global Vaccines Market
Leading Vaccine Manufacturers and Companies Searching for a Zika Virus Vaccine The number of patients infected with the Zika virus is predicted to soar, and the need for a vaccine is becoming ever more apparent. We discuss some of the leading international vaccine manufacturing companies, and then take a look at the companies that are currently developing vaccines or the Zika virus.
Companies included in this report include: • GlaxoSmithKline • Merck • Pfizer • Sanofi • Bharat Biotech • Inovio Pharmaceuticals
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What does the Zika virus outbreak mean for the future? Our new report discusses issues and events regarding the Zika virus outbreak, currently in Central and South America. You will find discussions, including analysis of past outbreaks, the virus’ modes of transmission, symptoms. Future trends include: • Increasing economic and social pressures related to the virus • Development of a vaccine will lead to large financial returns • The virus is likely to spread from its current territories, to include the US and possibly much of Southern Europe, Africa and Asia.
How the Zika Virus Report report helps you In summary, our 78-page report gives you the following knowledge: • Understanding of the structure, replication mechanisms and transmission modes of the Zika virus • An in-Depth history of previous Zika virus outbreaks and detail the viruses spread from Africa • Study of the potential spread of the virus, looking at the areas in which the virus’ vectors are able to survive on a global scale • Intelligence on important markets that will be affected by the Zika virus outbreak • Revenue forecast for the Infectious Disease Diagnostics Market covering the period 2016 to 2026 • Revenue forecast for the Global Vaccines Market covering the period 2016 to 2026. • Profiles of leading companies operating within the vaccines market • Significant social and economic issues arising from the spread of the Zika virus • Conclusions and recommendations
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the cholesterol-lowering drugs market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of Findings 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Key Questions Answered By This Analytical Report 1.5 Who Is This Report For? 1.6 Structure of the Report 1.7 Research and Analysis Methods 1.8 Exchange Rates 1.9 Frequently Asked Questions 1.10 Associated Visiongain Reports 1.11 About Visiongain
2. Introduction to Zika Virus 2.1 The Zika Virus 2.1.1 Flavivirus Structure 2.1.2 Zika Virus Replication Mechanism 2.1.3 Modes of Transmission 2.2 Outline of Previous Zika Outbreaks 2.3 Symptoms of ZIVD 2.3.1 Microcephaly
3. Zika Outbreak 2015/2016 3.1 The Progression of Zika in the Americas 3.2 Areas at Risk from Zika Infection 3.2.1 Areas with Ae.aegypti Populations 3.2.2 Areas with Ae.albopictus Populations 3.3 Containment Measures 3.3.1 Efforts in Affected Countries 3.3.2 Efforts in Un-Affected Countries 3.4 Basic Reproductive Number 3.4.1 Related Virus Basic Reproduction Numbers
4. Diagnostic Tools for the Detection of Zika Virus 4.1 The Infectious Disease Diagnostics Market 4.2 Infectious Disease Diagnostics Market Forecast, 2016-2026 4.3 Diagnosis of Zika Infection 4.3.1 Laboratory Tests for the Diagnosis of Zika Virus Disease 4.3.2 Commercial and Point-of-Care Tests 4.3.2.1 Biocan Diagnostics
5. Zika Virus Vaccine: Pipeline Candidates 5.1 Global Vaccine Market, 2014 5.2 Global Vaccine Market Forecast, 2016-2026 5.3 Leading Manufacturers of Human Vaccines 5.3.1 GlaxoSmithKline (GSK) 5.3.2 Merck & Co (MSD) 5.3.3 Sanofi 5.3.4 Pfizer 5.4 No Zika Virus Vaccine Currently Available 5.5 Zika Virus Vaccine Pipeline 5.5.1 Bharat Biotech 5.5.2 Sanofi Pasteur 5.5.3 Inovio Pharmaceuticals 5.5.4 Other Companies
6. Economic and Socio-Economic Effects of the Zika Virus Outbreak 6.1 Overview of Impact on Affected Nations 6.2 Zika Virus and Pregnancy in Affected Countries 6.3 Tourism and Major Events 6.3.1 Comparison with Other Viral Epidemics – Ebola Outbreak 2014 6.4 Healthcare Services and Support 6.5 Predicted Impact of Further Spread
7. Glossary
List of Tables Table 1.1 Currency Exchange Rates, 2015 Table 2.1 Modes of Infection of the Zika Virus and Their Confirmation Status Table 2.2 Number of Live Births (000’s) For a Selection of Countries in the Affected Region, 2011 Table 3.1 Countries/Territories with Active Zika Transmission as of 11th February 2016 Table 4.1 The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 5.1 The Global Vaccines Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.1 Countries at Risk of Infection and Number of Tourists (millions), 2013 Table 6.2 Number of Live Births in US States at High and Low Risk of Active Zika Transmission, and the Percentage of Live Births of Each (%) Table 6.3 Number of Live Births in US States at High Risk of Active Zika Transmission, 2014
List of Figures Figure 2.1 Representation of the Structure of a Flavivirus Figure 2.2 Representation of the Genome of a Flavivirus Figure 2.3 The Federated States of Micronesia, Location of 2007 Zika Virus Outbreak, with Yap Island Highlighted Figure 2.4 Map of Pacific Islands, with Area of French Polynesia Highlighted Figure 2.5 A Comparison of the Head Size of an Infant with Microcephaly and Without Figure 2.6 Cases of Suspected Microcephaly in Brazil from 2011 to 2016 Figure 3.1 Location of Camaçari, Brazil, First Location to Report Zika Virus in the Americas Figure 3.2 Population Density Map of Brazil, with Major Cities Labelled Figure 3.3 Areas Showing Zika Virus Transmission, December 2015 and January 2016, excluding Pacific Islands Figure 3.4 Likelihood of Occurrence of Ae.aegypti across the Americas Figure 3.5 Likelihood of Occurrence of Ae.aegypti across Europe and Africa Figure 3.6 Likelihood of Occurrence of Ae. aegypti across the Asia-Pacific Figure 3.7 Likelihood of Occurrence of Ae.albopictus across the Americas Figure 3.8 Likelihood of Occurrence of Ae.albopictus across Europe and Africa Figure 3.9 Likelihood of Occurrence of Ae.albopictus across the Asia-Pacific Figure 4.1 The Infectious Disease Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 4.2 Pan American Health Organization Zika Diagnosis Advice, 2015 Figure 5.1 The Global Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2014-2025 Figure 6.1 Percentage of Live US Births That Occurred in States with a High Risk and Low Risk of Active Zika Transmission, 2014
List of Organisations Centre for Disease Control European Centre for Disease Prevention and Control Fédération Internationale de Football Association (FIFA) Pan American Health Organisation The Catholic Church World Health Organisation
Download sample pages
Complete the form below to download your free sample pages for The Zika Virus Report
Download sample pages
Complete the form below to download your free sample pages for The Zika Virus Report
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.